Vascular endothelial growth factor

Stimulating blood vessel formation with magnets

Wednesday, July 21, 2021 - 11:00pm

This was used to treat endothelial cells, stimulating blood vessel formation.

Key Points: 
  • This was used to treat endothelial cells, stimulating blood vessel formation.
  • "We developed a promising cell therapy alternative that can non-invasively stimulate blood vessel formation or regeneration through the application of an external low-intensity magnetic field."
  • These cells can change into different cell types, and also secrete a protein called VEGF-A that stimulates blood vessel formation.
  • Finally, VEGF-A extracts produced by magnet-treated mesenchymal stromal cells on gelatin increased blood vessel formation in a chick embryo, although further research is needed to confirm these results.

OncXerna Therapeutics to Present at The LifeSci Partners Private Company Summer Symposium

Monday, July 19, 2021 - 12:00pm

WALTHAM, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc. (OncXerna), a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its first-in-class targeted oncology therapies, today announced that Laura Benjamin, Ph.D., Founder and CEO of OncXerna, will present at the LifeSci Partners Private Company Summer Symposium taking place virtually from July 21-23, 2021.

Key Points: 
  • WALTHAM, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc. (OncXerna), a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its first-in-class targeted oncology therapies, today announced that Laura Benjamin, Ph.D., Founder and CEO of OncXerna, will present at the LifeSci Partners Private Company Summer Symposium taking place virtually from July 21-23, 2021.
  • OncXernas approach pairs those patients with OncXernas clinical-stage therapies and known mechanism of action that directly address these biologies, with the goal to substantially improve patient outcomes.
  • OncXerna is targeting patients whose dominant tumor biology is driven by angiogenesis with a focus beyond VEGF to include broader anti-angiogenic pathways.
  • KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Notal Vision announces publication of first prospective longitudinal pilot study of daily self-imaging with patient-operated Home OCT in wet AMD patients

Tuesday, July 13, 2021 - 1:00pm

The study evaluated the ability of subjects to perform sequential daily self-imaging of their eyes with the user-friendly, tele-connected and self-operated Notal Home OCT device in their homes.

Key Points: 
  • The study evaluated the ability of subjects to perform sequential daily self-imaging of their eyes with the user-friendly, tele-connected and self-operated Notal Home OCT device in their homes.
  • Led by Prof. Loewenstein, the pilot study in Israel followed four patients undergoing routine anti-VEGF therapy for wet AMD in one or both eyes for up to three months.
  • Prospective longitudinal pilot study: daily self-imaging with patient-operated home OCT in neovascular age-related macular degeneration.
  • Notal Visions Home OCT system will enable wet AMD patients to perform technician-free OCTtesting at home with rapid and self-guided fixation critical components, especially for elderly patients frequently with pre-existing vision loss.

OXURION Completes Patient Enrollment for Part A of Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME)

Tuesday, June 8, 2021 - 6:00am

Dose selection data from Part A of the study is expected in the second half of 2021.

Key Points: 
  • Dose selection data from Part A of the study is expected in the second half of 2021.
  • THR-149 acts through inhibition of the plasma kallikrein-kinin (PKaI-Kinin) system, a validated VEGF-independent target for DME.
  • The Phase 2 KALAHARI study is a two part, randomized, prospective, multi-center study assessing multiple (3) injections of THR-149 in DME patients who suboptimally respond to anti-VEGF therapy.
  • This patient population currently does not have adequate treatment options and represents a critical area of unmet medical need in the treatment of diabetic macular edema.

EyePoint Pharmaceuticals Announces Completion of Enrollment of Phase 1 DAVIO Clinical Trial of EYP-1901 for the Potential Treatment of Wet AMD

Tuesday, May 25, 2021 - 12:00pm

We are pleased to report the completion of enrollment of all three dose cohorts in our ongoing Phase 1 trial of EYP-1901, said Nancy Lurker, CEO of EyePoint Pharmaceuticals.

Key Points: 
  • We are pleased to report the completion of enrollment of all three dose cohorts in our ongoing Phase 1 trial of EYP-1901, said Nancy Lurker, CEO of EyePoint Pharmaceuticals.
  • The completion of enrollment of our Phase 1 trial continues to make us confident that the potential advantages of EYP-1901 are obvious to patients and providers.
  • The ongoing Phase 1 DAVIO trial for EYP-1901 is an open-label twelve-month dose escalation trial examining wet AMD patients who were responsive to previous anti-VEGF therapies.
  • EYP-1901 is a potential twice-yearly sustained delivery intravitreal anti-VEGF treatment for wet age-related macular degeneration, currently being studied in a Phase 1 clinical trial.

aTyr Pharma Presents Preclinical Research Highlighting Mechanistic Insights into Tumor Inhibitory Effects of ATYR2810

Wednesday, May 19, 2021 - 1:00pm

ATYR2810 is a fully humanized monoclonal antibody that is designed to specifically and functionally block the interaction between NRP2 and one of its primary ligands, VEGF.

Key Points: 
  • ATYR2810 is a fully humanized monoclonal antibody that is designed to specifically and functionally block the interaction between NRP2 and one of its primary ligands, VEGF.
  • ATYR2810 is the first Investigational New Drug (IND) candidate to arise from aTyr\xe2\x80\x99s in-house research program designing monoclonal antibodies to selectively target the NRP2 receptor and its associated signaling pathways.
  • Preclinical data suggest that ATYR2810 could be effective against certain types of solid tumors.
  • aTyr\xe2\x80\x99s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases.

OncXerna Therapeutics to Present at Jefferies Virtual Healthcare Conference

Tuesday, May 18, 2021 - 1:00pm

b'WALTHAM, Mass., May 18, 2021 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its first-in-class targeted oncology therapies, today announced that Laura Benjamin, Ph.D., Founder and CEO of OncXerna, will present at the Jefferies Virtual Healthcare Conference taking place June 1-4, 2021.\nThe live presentation will occur on June 4, 2021 from 10:30 a.m. to 10:55 a.m.

Key Points: 
  • b'WALTHAM, Mass., May 18, 2021 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its first-in-class targeted oncology therapies, today announced that Laura Benjamin, Ph.D., Founder and CEO of OncXerna, will present at the Jefferies Virtual Healthcare Conference taking place June 1-4, 2021.\nThe live presentation will occur on June 4, 2021 from 10:30 a.m. to 10:55 a.m.
  • This allows OncXerna to pair those patients with OncXerna\xe2\x80\x99s clinical-stage therapies and known mechanism of action that directly address these biologies, to dramatically improve patient outcomes.
  • OncXerna is targeting patients whose dominant tumor biology is driven by angiogenesis with a focus beyond VEGF to include broader anti-angiogenic pathways.
  • OncXerna\xe2\x80\x99s clinical trials currently combine bavituximab with KEYTRUDA\xc2\xae to test the hypothesis that relieving immunosuppression can enhance responses to checkpoint inhibitors.

Gemini Therapeutics Completes Enrollment in Phase 2a Study of GEM103 as an Add-On to Anti-VEGF Therapy for the Treatment of Wet AMD Patients at Risk for Progressive Vision Loss Due to Macular Atrophy

Thursday, May 13, 2021 - 12:00pm

GEM103 delivered by intravitreal injection is designed to address both complement hyperactivity and restore retinal health in patients with AMD.

Key Points: 
  • GEM103 delivered by intravitreal injection is designed to address both complement hyperactivity and restore retinal health in patients with AMD.
  • In a genetically-defined subset of AMD patients, GEM103 may circumvent dysfunctional CFH loss-of-function variants and slow the progression of their retinal disease.
  • In patients undergoing anti-VEGF treatment, GEM103 may help regulate the hyperactive amplification of the alternative pathway believed to lead to cell loss and macular atrophy.
  • GEM103 is currently in a Phase 2a trial in dry AMD patients with a CFH risk variant and a Phase 1/2a study in patients with neovascular age-related macular degeneration with or at risk for macular atrophy.

4D Molecular Therapeutics Presents Non-Human Primate Preclinical Data at ASGCT on the 4D-150 Product Candidate for wet AMD and DME

Wednesday, May 12, 2021 - 10:30pm

The proliferation of abnormal blood vessels in the retina is stimulated by VEGF.

Key Points: 
  • The proliferation of abnormal blood vessels in the retina is stimulated by VEGF.
  • There are on average 200,000 new incidences of wet AMD per year in the United States alone.
  • The prevalence of DME is high, affecting approximately 1.1 million adults in the United States.\n4D-150 is designed as a dual transgene, intravitreal gene therapy inhibiting four distinct VEGF family members to prevent angiogenesis for the treatment of wet AMD and DME.
  • No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.\n'

Outlook Therapeutics to Host Virtual Clinical Day on May 20, 2021

Wednesday, May 12, 2021 - 1:05pm

With wet AMD, abnormally high levels of VEGF are secreted in the eye and lead to loss of vision.

Key Points: 
  • With wet AMD, abnormally high levels of VEGF are secreted in the eye and lead to loss of vision.
  • If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating a range of retinal diseases in the United States, United Kingdom, Europe, Japan, China and other markets.
  • Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway, initially for wet AMD.
  • For more information, please visit www.outlooktherapeutics.com .\n'